Here are 5 Biopharmaceutical Companies on the Rise

There are numerous bio-pharmaceutical companies developing potential groundbreaking treatments, and even cures, for diseases like Duchenne muscular dystrophy and rare types of Leukemia.

Market analysis publication, Seeking Alpha, has noted five such companies that have been, “working hard to advance medicine world-wide.” Among the list are Pluristem (NASDAQ:PSTI), Ariad Pharmaceuticals (NASDAQ:ARIA), Sarepta Therapeutics (NASDAQ:SRPT), Amicus Therapeutics (NASDAQ:FOLD), and StemCells (NASDAQ:STEM).

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Israel-based Pluristem develops placenta-based cell therapies that release therapeutic proteins in response to an array of local and systemic inflammatory diseases. In a press release dated August 6, the company announced its treatment, PuriX Bioreactor System, saved the life of a 54-year old woman suffering from an advanced form of lymphoma. “The treatment with PLX has saved her life and can certainly be classified as a medical miracle,” said the patient’s doctor, Professor Reuven Or, in the release. Furthermore, the company announced on August 13 that it may soon have an alternative to Bristol-Myer Squibb’s (NYSE:BMY) anti-clotting drug Plavix, which has been give an black box label by the FDA.

Ariad, a Massachusetts-based biotechnology company focused on cancer research, has been working on a treatment for patients with hematologic cancers, including chronic myeloid leukemia, call Ponatinib. While the company has only just reported its phase II trial results to the American Society of Clinical Oncology, the FDA has allowed Ariad to treat patients through compassionate use, which allows certain qualified patients to receive treatment before the drug is approved. The company expects FDA approval in early 2013.

Sarepta Therapeutics made headlines at the start of October after trial data showed its new treatment for Duchenne muscular dystrophy helped patients walk farther. The announcement pushed the company’s stock price up 165 percent to $39.67.

Further advancements in treatments for genetic diseases have been made by Amicus Therapeutics and StemCells announced on October 4 that the company has made steps towards curing macular degeneration through transplants.

Don’t Miss: Here’s Another Misstep for Pfizer to Explain.